Table 4.
Immune-related adverse events occurring in patients before and during COVID-19 course
|
Patient No.
|
Tumor Type
|
Last ICI Regimen
|
Prior to COVID-19 Diagnosis
|
During COVID-19 Diagnosis
|
||
|
irAE No. 1 (Grade)
|
irAE No. 2 (Grade)
|
irAE No. 3 (Grade)
|
irAE No. 1 (Grade)
|
|||
| 2 | Melanoma | Nivolumab | Colitis (3) | Hepatitis (3) | Pancreatitis (2) | |
| 11 | Lung | Durvalumab | Dermatitis (2) | |||
| 27 | Oropharyngeal | Pembrolizumab | Hepatitis (1) | Dermatitis (1) | ||
| 19 | Melanoma | Pembrolizumab | Pancreatitis (3) | Hepatitis (1) | Hypophysitis (3) | Hypophysitis (3)a |
| 23 | Skin cancer | Cemiplimab | Dermatitis (2) | |||
| 9 | Lung | Pembrolizumab | Pneumonitis (3) | |||
| 3 | Lung | Pembrolizumab | Hypophysitis (3) | Hypophysitis (3)a | ||
| 5 | Esophageal | Pembrolizumab | Hypothyroidism (3)b | |||
COVID-19: coronavirus disease 2019; ICI: immune checkpoint inhibitor; irAE: immune-related adverse event
a
Persistent irAE continuing during COVID-19 course
b
New irAE developing during COVID-19 course